GE salmon: a precedent-setting approval

Mary Budinger

· February/March 2013

GE salmon: a precedent-setting approval

Despite some 400,000 public comments opposing genetically engineered (GE) salmon, the Food Drug Administration (FDA) announced on December 26, 2012, that it is prepared to give transgenic salmon its final stamp of approval. The FDA issued a positive environmental assessment a preliminary “finding of no significant impact.” The public comment period closes on February 25, 2013.

AquaBounty Technologies, a U.S. company, has spent 17 years more than $60 million creating marketing GE Atlantic salmon. This would be the very first GE animal food sold for human consumption.

The fish, called AquaAdvantage® salmon, maturity twice as fast — 18 months instead of 36 months — grow twice as large as natural Atlantic salmon. AquaBounty scientists inserted a growth-hormone gene from Chinook salmon also a gene from the ocean pout (blenny-like eel-like in form) that activates the growth hormone. Thus AquaAdvantage Atlantic salmon are genetically engineered to produce growth hormones year-round, instead of only in warm weather months as normal salmon do.

This new creation comes with two promises: (1) GE salmon are sterile will be raised exclusively in shore-based, closed containment tanks, and (2) GE salmon will reduce the stress on the wild stock because they eat least one-third less feed than conventional farmed salmon do to harvest weight.

Health concerns


Consumers Union senior scientist Michael Hansen testified to the FDA in 2010 about serious flaws in the few safety studies.

“The evidence of the FDA’s evaluation of the AquAdvantage salmon suggests that the FDA has set the bar very low. There is sloppy science, small sample sizes, questionable practices (manipulating IGF-1 data). … Because the FDA’s assessment is inadequate, we are particularly concerned that this salmon may pose an increased risk of severe, even life-threatening allergic reactions to sensitive individuals.”

Just six fish were used in the company’s studies on the potential of the GE fish to cause an allergic reaction. The studied GE fish were found to be 19 percent more allergenic than non-GE fish in the control group.

Dr. Anne Kapuscinski, a professor of environmental studies Dartmouth College, specializes in environmental risk assessment in aquaculture systems. She found the FDA’s process lacking.

“There were a lot of things in the way they presented their approach to risk assessment a lot of what we saw in the environmental assessment that was released to the public suggested that they are not on the cutting edge of the state-of-the-art of risk assessment science,” Kapuscinski said. “They need to be on that cutting edge when we’re dealing with a precedent-setting case, one that is challenging because we’re dealing with an animal that’s barely domesticated. Farmed salmon is a global commodity.”

Wenonah Hauter, Executive Director of Food & Water Watch, pointed out that it appears unlikely the GE salmon will be labeled as such.

More than 40 members of Congress scientists other federal agencies, including the National Oceanic Atmospheric Administration the U.S. Fish Wildlife Service, have also voiced strong opposition to GE salmon, citing the lack of transparency, scientific rigor expertise the FDA.

The FDA is treating transgenic animals as new drug applications, which means much of the agency’s deliberations are conducted in secret. The FDA does not conduct its own testing of genetically engineered animals: It relies on information provided by the company seeking approval. In the FDA’s view, the refashioned DNA that is in every cell of the fish’s body is considered a drug, which is what the agency is regulating.

Genetic drift lessons from Jurassic Park?


The GE fish were created a facility on Canada’s Prince Edward Island. Eggs are shipped to Panama where they adulthood in inland tanks with multiple barriers to escape.

Farmed salmon, by contrast, are raised in the ocean in offshore pens. This creates a crowded, unnatural situation that is proven to promote disease generate parasites that can devastate wild salmon swimming in the area. Inland tanks are considered much less hazardous than ocean pens. Even critics admit that inland tanks represent a huge improvement in ocean stewardship.

AquaBounty says it will sell their GE salmon only to farmers who will raise them in enclosed inland tanks. Environmentalists anticipate that over time, however, some salmon farmers may make use of cheaper, offshore pens since no one is policing them.

The GE fish are sterile females. However, according to the warning letter members of Congress sent to the FDA in 2010, AquaBounty’s own studies “suggest that five percent of its eggs may not be sterile, it plans to produce millions of eggs.”

Critics point to previous GE mishaps. In the late 1990s, for example, the GE corn StarLink™ was approved only for non-food uses since it contained a potentially allergenic protein. But whoops — traces of it started turning up in the food supply, including in Taco Bell® taco shells.

The main concern addressed by the FDA was whether GE salmon could escape the tanks establish themselves in the wild, with detrimental environmental consequences. The FDA concluded that the chance that would happen was “extremely remote.”

Coming to a dinner table near you


The public comment period for GE salmon is open until February 25, 2013. You can submit comments Make it clear that your comments refer to Docket No. FDA–2011–N–0899.

AquaBounty said that if the approval came early this year, some salmon could American dinner plates by the end of the year. But quantities would be limited by the small capacity in Panama. The AquaBounty fish will be processed in Panama, salmon fillets steaks will then be transported to the U.S.

AquaBounty hopes to sell eggs to other fish farms that would grow larger quantities of salmon, but that is likely to take a few more years.

Mary Budinger is an Emmy award-winning journalist who writes about integrative medicine..

Reprinted from AzNetNews, Volume 32, Number 1, February/March 2013.

Found this helpful? Share it with someone who needs it.